Need help with ordering? Contact us at 1-877-468-3832

States WHERE Tanovea-CA1 is Currently Available for Purchase

VetDC is working towards securing appropriate licensure to sell TANOVEA-CA1 in all 50 states. If your state is not listed below, please sign up at tanovea.com to receive notification as additional states are added.

AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IA, IL, IN, KS, KY, LA, MA, MD, ME, MO, MS, MT, NC, ND NE, NH, NJ, NV, NY, OK, OR, PA, RI, SC, SD, TX, UT, VA, WA, VT, WV, WI, WY

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.

Important Safety Information: TANOVEA-CA1 is indicated for the treatment of lymphoma in dogs. In clinical trials, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA-CA1. Do not use in West Highland White Terriers and use with caution in other terrier breeds. Owners should take extra care when handling and cleaning up after their dog for five days after treatment. Please see the package insert for full prescribing information, warnings and precautions.